Non-alcoholic Steatohepatitis Biomarkers Market (2026 - 2033)

Non-alcoholic Steatohepatitis Biomarkers Market Summary

The global non-alcoholic steatohepatitis biomarkers market size was valued at USD 2.0 billion in 2025 and is projected to grow from USD 2.5 billion in 2026 to USD 9.2 billion by 2033, growing at a CAGR of 20.4% from 2026 to 2033. North America dominated the market, accounting for the largest global share of 53.8% in 2025. The increasing prevalence of chronic liver diseases, particularly Non-alcoholic Steatohepatitis (NASH), is significantly expanding the market for NASH biomarkers.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

Growing awareness and advancements in diagnostics are the major driving factors encouraging the demand for early detection and better management of the disease. Novel diagnostic tests offer more accurate, noninvasive ways to assess liver damage, thus boosting the adoption of biomarkers for personalized treatment plans. With NASH cases on the rise globally, healthcare providers are increasingly relying on these biomarkers, propelling the market growth and encouraging innovation in diagnostic solutions.

To learn more about this report, Download Free Sample Report

NASH has been one of the most difficult diseases for the diagnostics industry to manage, owing to non-specific or silent symptoms, which resulted in patients being unaware until the late stages of the disease. This hinders the diagnosis of the disease, limiting the overall growth of the market. Studies are being conducted to develop novel functional tests. These tests measure changes in liver function before the condition progresses the fibrosis. In addition, breath tests are being considered the detect molecules and compounds associated with NASH. These tests are projected to provide robust information and compete with biomarker tests.

Market Dynamics

The Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market is driven by the rising prevalence of obesity, type 2 diabetes, and metabolic dysfunction-associated liver disease, increasing demand for non-invasive diagnostic solutions, and growing clinical trial activity for NASH therapeutics. Advancements in serum and imaging biomarkers, as well as multi-omics technologies, are improving early disease detection and patient stratification. Favorable research funding and pharmaceutical partnerships further support market growth. However, regulatory challenges, biomarker validation requirements, and the lack of standardized diagnostic pathways may restrain adoption.

Analyst Perspective

The Non-Alcoholic Steatohepatitis (NASH), increasingly referred to as Metabolic Dysfunction-Associated Steatohepatitis (MASH) biomarkers market is experiencing strong growth due to the rising prevalence of obesity, type 2 diabetes, and metabolic liver disease. Growing demand for non-invasive alternatives to liver biopsy is accelerating adoption of serum biomarkers, fibrosis markers, metabolomic signatures, and imaging-based diagnostics. Recent approvals of NASH/MASH therapies are further increasing the need for accurate disease identification, staging, and treatment monitoring. Companies are focusing on multi-biomarker panels, AI-enabled diagnostics, and companion diagnostics, supported by collaborations across diagnostic, pharmaceutical, CRO, and academic organizations. Despite regulatory and reimbursement challenges, advances in precision medicine are expected to strengthen the role of biomarkers in liver disease management and drug development.

Type Insights

Based on type, the serum biomarker segment led the market with the largest revenue share of 32.7% in 2025 due to its noninvasive nature and ability to provide critical insights into disease progression. These biomarkers offer convenience and efficiency, enabling early detection and monitoring of NASH without the need for invasive liver biopsies. Furthermore, serum biomarkers are cost-effective and suitable for routine clinical use, driving their adoption among healthcare professionals. Their effectiveness in assessing liver inflammation, fibrosis, and overall metabolic dysfunction further solidifies their dominance in the market.

The hepatic fibrosis biomarkers segment is anticipated to grow at a significant CAGR over the forecast period, attributed to their pivotal role in assessing liver damage and fibrosis progression. These biomarkers enable early identification of advanced fibrosis stages, which is crucial for determining disease severity and treatment options. The growing demand for noninvasive diagnostic tools further boosts their adoption, as they help avoid costly and uncomfortable liver biopsies. Moreover, advancements in biomarker technology and their potential for personalized treatment plans are anticipated to drive significant growth in this segment.

End Use Insights

The pharma & CRO industry segment led the market with the largest revenue share of 40.7% in 2025. Pharmaceutical companies focus on developing therapies for NASH, creating a strong demand for reliable biomarkers to monitor disease progression and treatment responses. CROs contribute by providing specialized services for clinical trials, helping pharmaceutical companies efficiently validate biomarkers. This collaboration accelerates the identification of effective treatments, boosting the market share of the pharma and CRO industries in the NASH biomarker space.

To learn more about this report, Download Free Sample Report

The diagnostic labs segment is expected to witness a significant CAGR during the forecast period, driven by the growing demand for early detection and personalized treatment of NASH. These labs play a vital role in identifying biomarkers that help diagnose the disease at its onset, enabling more effective management. The rising global prevalence of NASH, coupled with advancements in biomarker testing technologies, drives the demand for diagnostic services. Growing awareness and a shift toward noninvasive diagnostic methods further enhance the segment's potential in the non-alcoholic steatohepatitis biomarkers industry.

Regional Insights

The North America non-alcoholic steatohepatitis biomarkers market accounted for the largest revenue share of 53.8% in 2025. This share is attributable to the increasing diagnosis rate of NASH. Enhanced awareness and better diagnostic technologies aid in the accurate detection of the disease. In addition, the early launch of novel products and biomarkers in the market fosters innovation and improves treatment outcomes. This combination of higher diagnosis rates and the introduction of advanced tools is accelerating the growth of the non-alcoholic steatohepatitis biomarkers industry in North America, driving demand for more effective and tailored diagnostic solutions.

To learn more about this report, Download Free Sample Report

U.S. Non-alcoholic Steatohepatitis Biomarkers Market Trends

The U.S. held the largest share of NorthAmerica non-alcoholic steatohepatitis biomarkers market in 2025. The growing prevalence of NASH in the U.S., driven by rising obesity and diabetes rates, is significantly boosting the demand for NASH biomarkers. Increased awareness about disease and the need for early detection are compelling healthcare providers to adopt advanced diagnostic methods. Noninvasive testing technologies, including blood biomarkers and imaging techniques, are gaining popularity for their accuracy, safety, and cost-effectiveness, thereby reducing the need for invasive liver biopsies. These innovations fuel market growth and encourage the development of more precise and accessible NASH diagnostic tools.

Europe Non-alcoholic Steatohepatitis Biomarkers Market Trends

Europe non-alcoholic steatohepatitis biomarkers market is anticipated to experience significant expansion over the forecast period. The growing emphasis on early detection and diagnosis of NASH significantly boosts the demand for biomarkers in Europe. Early intervention can improve treatment outcomes, reducing the risk of severe liver damage. Furthermore, the shift toward personalized treatment plans tailored to individual patients' needs is encouraging the development of more precise biomarkers. This dual focus on early detection and customized therapies is expected to drive the growth of the non-alcoholic steatohepatitis biomarkers industry in Europe as healthcare providers seek more accurate and efficient diagnostic tools.

Asia Pacific Non-alcoholic Steatohepatitis Biomarkers Market Trends

Asia Pacific non-alcoholic steatohepatitis biomarkers market is set to be the fastest-growing region over the forecast period, due to expanding healthcare infrastructure and increasing R&D investments by biotech companies. Enhancing regional healthcare facilities enables better diagnostic capabilities and access to advanced biomarkers. Biotech companies are significantly investing in research and development to discover more accurate, noninvasive biomarkers, addressing the rising demand for early-stage NASH detection. This collaborative push toward innovation is expected to accelerate market growth by improving diagnostic accuracy, treatment outcomes, and overall disease management in the region.

India Non-alcoholic Steatohepatitis Biomarkers Market Trends

India non-alcoholic steatohepatitis biomarkers market is projected to grow at the fastest CAGR in the regional market during the forecast period, fueled by the increasing demand for noninvasive diagnostic methods in the country. Patients and healthcare providers prefer noninvasive approaches to avoid the discomfort and risks associated with liver biopsies. Moreover, advancements in biomarker discovery technologies are improving the accuracy and efficiency of diagnosing NASH, leading to better early detection and monitoring of the disease. These factors are expected to significantly expand the market, offering innovative solutions to meet the growing healthcare needs in India.

Key Non-alcoholic Steatohepatitis Biomarkers Company Insights

Some of the key companies in the non-alcoholic steatohepatitis biomarkers industry include Siemens Healthineers AG, AstraZeneca, Labcorp, Pfizer Inc., and Bristol-Myers Squibb Company.

• Pfizer Inc. provides innovative healthcare solutions, including vaccines, biologics, and prescription medications. Its products target a wide range of conditions, including cancer, cardiovascular diseases, infectious diseases, and immunological disorders, thereby enhancing global health outcomes.

• Bristol-Myers Squibb Company offers innovative medicines, with a focus on oncology, immunology, cardiology, and fibrosis. Its portfolio includes biologics, small molecules, and cell therapies, aimed at addressing serious diseases and improving patient outcomes globally.

Key Non-alcoholic Steatohepatitis Biomarkers Companies

The following key companies have been profiled for this study on the non-alcoholic steatohepatitis biomarkers market.

• GENFIT

• Prometheus Laboratories

• Siemens Healthineers AG

• BioPredictive

• Quest Diagnostics

• AstraZeneca

• Exalenz Bioscience Ltd. (Meridian Bioscience; majority-owned by SD Biosensor)

• Labcorp

• Pfizer Inc.

• Bristol-Myers Squibb Company

Recent Developments

• In August 2025, the U.S. Food and Drug Administration (FDA) accepted a Letter of Intent proposing liver stiffness measurement by vibration-controlled transient elastography (VCTE) as a reasonably likely surrogate endpoint for all-cause mortality or liver-related events in clinical trials involving adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate-to-advanced liver fibrosis. The proposed biomarker offers a non-invasive approach for assessing liver stiffness and fibrosis severity and may support evaluation of disease progression and treatment response.

• In July 2024, SomaLogic, a leading protein biomarker discovery and clinical diagnostics company, introduced new biomarkers and provided mechanistic and clinical insights into Acetyl CoA Carboxylase (ACC) for the diagnosis of Non-alcoholic Steatohepatitis (NASH).

Global Non-alcoholic Steatohepatitis Biomarkers Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends across sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global non-alcoholic steatohepatitis biomarkers market report on the basis of type, end use, and region:

To learn more about this report, Download Free Sample Report

• Type Outlook (Revenue, USD Million, 2021 - 2033)

  • Serum Biomarkers

  • Hepatic Fibrosis Biomarkers

  • Apoptosis Biomarkers

  • Oxidative Stress Biomarkers

  • Others

• End Use Outlook (Revenue, USD Million, 2021 - 2033)

  • Pharma & CRO Industry

  • Hospitals

  • Diagnostic Labs

  • Academic Research Institutes

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Research Methodology

The non-alcoholic steatohepatitis biomarkers market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing - reconciling supply-side and demand-side estimates - and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each non-alcoholic steatohepatitis biomarkers segment quantified using the revenue-capture definitions in the table below.

Estimation Model

The NASH biomarkers market size is estimated using a combination of top-down and bottom-up approaches. The bottom-up methodology evaluates revenues generated from biomarker assays, diagnostic panels, imaging biomarkers, laboratory services, and research-use products across key end-user segments, including pharmaceutical companies, CROs, hospitals, diagnostic laboratories, and academic institutions. The top-down approach assesses the addressable patient population with MASLD/NASH, biomarker testing rates, adoption of non-invasive diagnostics, and healthcare expenditure trends. Market estimates are validated through analysis of company annual reports, regulatory publications, peer-reviewed journals, clinical trial databases, healthcare statistics, and expert interviews. Data triangulation is applied across product type, biomarker category, end user, and geographic region to ensure accuracy and consistency of market forecasts.

To learn more about this report, Download Free Sample Report

Delivered Customizations

This report has been delivered with the following In-depth customizations